Plus Therapeutics Gets DSMB Approval To Start Eighth Cohort For Glioblastoma Trial
The Data and Safety Monitoring Board has recommended Plus Therapeutics Inc (NASDAQ:PSTV) to proceed to the eighth cohort of Phase 1…
The Daily Biotech Pulse: Regeneron COVID-19 Antibody Cocktail Data, FDA Nod For Mallinckrodt, Molecular Partners IPO
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 15)
Parbec Delivers Additional Significant Gold Intervals, Surimeau Program Update
- PAR-21-128 delivers 12.6m grading 4.39 g/t gold, as measured in the core box, including a sub-interval of 4.1m of 9.3 g/t gold.
China Plans To Crackdown On Private Tutoring Companies: Reuters
China is planning a tough crackdown on the country's $120 billion private tutoring industry, Reuters reported.
These OTC Securities had the Most Trading Activity in May
Photo by Karsten Winegeart on Unsplash
MannKind – United Therapeutics’ Formulated Treprostinil Under FDA Review For Pulmonary Hypertension
MannKind Corporation (NASDAQ:MNKD) and United Therapeutics Corporation (NASDAQ:UTHR) have announced that the FDA has accepted for review the marketing application of Tyvaso DPI…
24 Stocks Moving in Wednday’s Pre-Market Session
Gainers
Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB) rose 43.6% to $2.93 in pre-market trading after a 13G filing from Ra Capital showed a 7.5% stake in the company.
VEON Acquires Russian AdTech Platform OTM For Undisclosed Sum
Connectivity and internet services provider VEON Ltd (NASDAQ:VEON) has acquired a majority stake in OTM, a technology platform for automating and planning…
Inhibikase Therapeutics Stock Drops After Follow-On Equity Offering Of $45M Issued At 26% Discount
Inhibikase Therapeutics Inc (NASDAQ:IKT) has priced an underwritten public offering of 15 million shares at $3/share for gross proceeds of approximately…
Aptinyx Provides Updates On Mid-Stage NYX-783 Program In PTSD Patients
After a Type C meeting with the FDA, Aptinyx Inc (NASDAQ:APTX) has finalized the design of its Phase 2b program for NYX-783…